On the basis of the results obtained, it is justified to hypothesize that a combined therapy consisting of ABL1 TKIs and PI3K/Akt/mTOR inhibitors may offer a new therapeutic option for T-ALL patients carrying NUP214-ABL1 fusion kinase to overcome the resistance to TKIs. The gene discussed is ABL1; the disease is acute lymphoblastic leukemia.